Contract Renewed on Operation and Maintenance (O&M) Services for APM System at Washington Dulles International Airport

TOKYO, Dec 20, 2024 - (JCN Newswire via SeaPRwire.com) - Crystal Mover Services, Inc. (CMSI), a part of Mitsubishi Heavy Industries (MHI) Group, that is engaged in operation and maintenance (O&M) of automated people mover (APM(Note1)) systems for U.S. airports, has successfully renewed a contract with the Metropolitan Washington Airports…

Enablement of JCB Contactless Payment at All NJ TRANSIT Contactless Bus and Light Rail Validators in New Jersey, New York, and Pennsylvania

TOKYO & LOS ANGELES, Dec 19, 2024 - (JCN Newswire via SeaPRwire.com) - JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd., Japan's only international payment brand (JCB), and JCB International Credit Card Co., Ltd. (JCB USA), the US subsidiary of JCB Co., Ltd., are pleased to announce…

NEC Receives Telecom Review’s Global Excellence Award for Innovative Telecom B2B/ Enterprise Network Solutions

TOKYO, Dec 18, 2024 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701), a leading global IT and network transformation services provider, has been selected as winner of the Most Innovative Product/Service/Automation (Vendor) Global at the Telecom Review Leaders’ Summit 2024. NEC received this award for Telecom B2B/…

MHI’s Automated Picking Solution Utilizing Sigma Synx Fully Implemented at Kirin Group’s Ebina Logistics Center, the First Such System in Japan

- Supporting automation and labor savings with a smart picking system that efficiently links AGFs, AGVs, and palletizers through the ΣSynX system for automation and intelligence- Accelerating the response to 2024 regulatory changes and to the challenges facing logistics centers, including a shortage of operators, heavy manual labor and long…

NEC Announces Interim Results from Phase 1 Clinical Trial of NECVAX-NEO1, an AI-Driven Personalized Oral Cancer Vaccine, at ESMO Immuno-Oncology Congress 2024

TOKYO, Dec 12, 2024 - (JCN Newswire via SeaPRwire.com) - NEC Bio Therapeutics today presents 24-week promising interim results from an ongoing Phase 1 basket clinical trial of an orally administered cancer vaccine, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPI) for treating patients with solid tumors. The findings are…